<DOC>
	<DOCNO>NCT00087503</DOCNO>
	<brief_summary>This international , multicenter , uncontrolled , 2-stage , phase II study adult patient advance gastric cancer , reasonable performance status , good organ function , lack serious concomitant medical condition . Patients must progress recur fluoropyrimidine-containing regimen anytime primary metastatic disease within 6 month last dose adjuvant therapy . Twenty-one evaluable patient enrol Stage 1 . If least 2 objective tumor response observe first 21 evaluable patient , study expand enroll total 41 evaluable patient . Edotecarin administer start dose 13 mg/m2 IV infusion 60 minute repeat 3-week cycle treatment .</brief_summary>
	<brief_title>Intravenous Edotecarin Patients With Advanced Gastric Cancer That Has Progressed Recurred After Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis gastric adenocarcinoma gastroesophageal junction adenocarcinoma ( i.e. , adenocarcinoma &gt; 50 % extension stomach ) Presence locally advance metastatic disease nonamenable surgery +/ chemoradiation curative intent Progression recurrence fluoropyrimidinecontaining regimen time primary metastatic disease within 6 month last dose adjuvant therapy Presence least 1 measurable ( target ) lesion . Target lesion defined lesion measure least 1 dimension &gt; =20mm conventional technique &gt; =10mm spiral computerize tomography ( CT ) scan . Previously irradiate lesion consider target lesion . All previous therapy must discontinue least 4 week study entry , acute toxic effect ( exclude alopecia neurotoxicity ) prior therapy must resolve NCI CTC ( Version 2.0 ) Grade &lt; =1 ( please see inclusion criterion # 8 exception ) Age &gt; = 18 year ECOG performance status 0 , 1 2 Baseline test within follow limit : Absolute neutrophil count ( ANC ) &gt; = 1500/mm3 ( 1.5 x 10 ( 9 ) /L ) Platelets &gt; = 100,000/mm3 ( 100 x 10 ( 9 ) /L ) Hemoglobin &gt; = 9.0 g/dL Serum creatinine &lt; = 1.5 mg/dl ( &lt; = 133 mmol/L ) Total serum bilirubin &lt; = 1.5 x upper limit normal ( ULN ) regardless liver involvement secondary tumor SGOT &lt; = 2.5 x ULN ; &lt; =5 x ULN liver involvement secondary tumor Albumin &gt; =3.0 g/dL Pregnancy test female childbearing potential negative within 7 day start treatment Evidence personally sign date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect trial Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure Prior treatment another topoisomerase I inhibitor More 1 prior chemotherapy regimen advance disease Prior radiation therapy &gt; 25 % bone marrow Any investigational agent receive 4 week enrollment study and/or current enrollment another therapeutic clinical trial Previous highdose chemotherapy require hematopoietic stem cell rescue Known brain metastasis , spinal cord compression , carcinomatous meningitis ( baseline CT magnetic resonance imaging ( MRI ) scan brain required case clinical suspicion central nervous system metastasis ) Previous ( within last 5 year ) current malignancy site , except adequately treat basal cell squamous cell skin cancer situ carcinoma cervix uteri Active inflammatory bowel disease , partial complete bowel obstruction chronic diarrhea Any follow past 6 month : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism , deep vein thrombosis significant thromboembolic event Ongoing cardiac dysrhythmias NCI CTC grade &gt; =2 , atrial fibrillation grade Active infection , include know human immunodeficiency virus ( HIV ) positivity Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration may interfere interpretation study result , judgement investigator , would make subject inappropriate entry study Pregnancy breastfeeding . Female patient must surgically sterile postmenopausal , must agree use effective contraception period therapy . Fertile patient refuse use reliable contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>